Compliance to Advisory Committee on Immunization Practices recommendations for pneumococcal vaccination

Morga, Antonia; Kimura, Tomomi; Feng, Qi; Rozario, Nigel; Schwartz, Jason J.

doi:10.1016/j.vaccine.2022.03.005

Cited by 7 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several small studies suggest series completion is poor among adults in Germany for whom sequential vaccination (i.e., with PCV13→PPV23) is currently recommended, and similar trends have been observed in the US. [40][41][42][43][44] Thus, the availability of a single dose PCV20 strategy will likely improve vaccine uptake, leading to greater benefit in terms of pneumococcal disease prevention. The simplicity of a single dose strategy for pneumococcal disease prevention among adults may also reduce burden on providers, payers, and the healthcare system on the whole.…”

Section: Discussionmentioning

confidence: 99%

Cost-effectiveness of use of 20-valent pneumococcal conjugate vaccine among adults in Germany

Kuehne

Achtert²,

Pueschner³

et al. 2023

Preprint

View full text Add to dashboard Cite

Objectives. Despite national recommendations for use of pneumococcal vaccines, rates of community-acquired pneumonia (CAP) and invasive pneumococcal disease (IPD) remain high in Germany. New pneumococcal conjugate vaccines (PCVs) with expanded coverage have the potential to reduce the pneumococcal disease burden among adults. Methods. Using a Markov model, we evaluated the lifetime outcomes/costs comparing 20-valent PCV (PCV20) with standard of care (SC) vaccination for prevention of CAP and IPD among adults aged 60 years and at-risk adults aged 18-59 years in Germany. PCV20 also was compared with sequential vaccination with 15-valent PCV (PCV15) followed by PPV23 in a scenario analysis. Results. Use of PCV20 vs. SC would prevent 54,333 hospitalizations, 26,368 outpatient CAP cases, 10,946 disease-related deaths yield 74,694 additional life-years (LYs), while lowering total medical costs by 363.2M Euro. PCV20 was cost saving (i.e., dominant) versus SC. Scenario analysis results suggest that the use of PCV20 would also prevent more cases and deaths, yield more LYs, and result in lower costs than using PCV15→PPV23. Conclusions. One dose of PCV20 among adults aged 60 years and adults aged 18-59 years with moderate- and high-risk conditions would substantially reduce pneumococcal disease, save lives, and be cost saving compared with SC.

show abstract

Section: Discussionmentioning

confidence: 99%

Cost-effectiveness of use of 20-valent pneumococcal conjugate vaccine among adults in Germany

Kuehne

Achtert²,

Pueschner³

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…10,13 In Hong Kong, the current recommendations for pneumococcal vaccination by the Centre for Health Protection prioritise adults aged ≥65 years with high-risk conditions, 17 consistent with recommendations from the United States Advisory Committee on Immunisation Practices. 18 Specifically, pneumococcal vaccine-naïve individuals with high-risk conditions are recommended to receive one dose of PCV13, followed by one dose of PPSV23 at 1 year after PCV13 vaccination. 17 Since 2017, the Hong Kong government has provided free or subsidised pneumococcal vaccination to eligible individuals through the Government Vaccination Programme (GVP) and the Vaccination Subsidy Scheme (VSS).…”

Section: Burden Of Invasive Pneumococcal Disease In Hong Kongmentioning

confidence: 99%

The role of a single-shot higher-valency pneumococcal vaccine in overcoming challenges regarding invasive pneumococcal disease in Hong Kong

Hui¹,

Lam

Lin³

et al. 2023

Hong Kong Med J

View full text Add to dashboard Cite

“…13,14 While the CDC has stressed the importance of these protective preoperative vaccinations, the overall rates of both PCV13 and PPSV23 in children and adults undergoing cochlear implantation are rather variable among the reported literature. 15,16 Furthermore, the reported quality improvement (QI) interventions designed to increase pneumococcal vaccination rates display successes that could potentially be implemented on a larger scale at other cochlear implant centers. Therefore, we performed a comprehensive systematic review and meta-analysis of documented PCV13 and PPSV23 vaccination rates among CI recipients at baseline and rates following a QI intervention.…”

mentioning

confidence: 99%

Improving Pneumococcal Vaccination Rates in Cochlear Implant Programs: A Systematic Review and Meta‐analysis

Britt

Poupore

Nguyen

et al. 2022

Otolaryngol.--head neck surg.

View full text Add to dashboard Cite

Objective To review the literature on pneumococcal vaccination compliance rates among cochlear implant (CI) patients and to examine the utility of intervention programs on increasing vaccination rates. Data Sources PubMed, Scopus, and CINAHL. Review Methods A systematic review was performed following PRISMA guidelines. Studies of pneumococcal vaccination rates at baseline and before and after the implementation of a quality improvement (QI) intervention were included. A total of 641 studies were screened, and 13 studies met inclusion criteria. Meta-analyses of pneumococcal vaccination rates pre- and post-QI intervention in CI patients were performed. Results A total of 12,973 children and adults were included. The baseline PCV13 and PPSV23 vaccination rates were 53.45% (95% CI, 37.02%-69.51%) and 42.53% (95% CI, 31.94%-53.48%), respectively. Comparing children and adults, PCV13 and PPSV23 baseline vaccination rates were not statistically significant. The PPSV23 vaccine rate after QI initiatives was significantly higher than the baseline rate at 83.52% (95% CI, 57.36%-98.46%). After these interventions, patients had a 15.71 (95% CI, 4.32-57.20, P < .001) increased odds of receiving PPSV23 vaccination compared to before QI implementation. Conclusions The baseline rates of PCV13 and PPSV23 are highly variable and lower than expected, given current vaccination recommendations for CI patients. QI programs appear successful in increasing compliance rates with the PPSV23 vaccination; however, they are still far from full compliance. Further intervention programs with stricter surveillance, monitoring, and follow-up systems are needed to achieve improved compliance with the PCV13 and PPSV23 vaccination in CI recipients.

show abstract

Compliance to Advisory Committee on Immunization Practices recommendations for pneumococcal vaccination

Cited by 7 publications

References 12 publications

Cost-effectiveness of use of 20-valent pneumococcal conjugate vaccine among adults in Germany

Cost-effectiveness of use of 20-valent pneumococcal conjugate vaccine among adults in Germany

The role of a single-shot higher-valency pneumococcal vaccine in overcoming challenges regarding invasive pneumococcal disease in Hong Kong

Improving Pneumococcal Vaccination Rates in Cochlear Implant Programs: A Systematic Review and Meta‐analysis

Contact Info

Product

Resources

About